A Study of the Characteristics and Outcomes of Treatment for C. Diff in Post-Transplant Patients


About this study

The purpose of this study is to estimate the success, recurrence, and complications over the 90 day follow up period for the treatment of C. difficile infection in adult solid organ or stem cell transplant patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years
  • Signed informed consent
  • Transplant recipient (solid organ, stem cells, or bone marrow) within past 2 years
  • Currently diagnosed with first CDI after transplant, defined by 
    • Presence of diarrhea (at least 3 loose stools within a 24-hour period)
    • Detection of C. difficile cytotoxin in stools by
      • Cytotoxin assay
      • Toxigenic culture
      • Polymerase chain reaction (PCR) testing
      • Enzyme immunoassay
    • Endoscopic presence of pseudomembranes with the detection of C. difficile in tissue biopsies

Exclusion Criteria

  • Previous episode of CDI anytime after transplant
  • Current treatment for another infectious cause of diarrhea (bacterial, viral, or parasitic) at the time of the current CDI diagnosis

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Zelalem Temesgen, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer